PT-141, VIP, and related pathway compounds.

Sexual health research compounds include melanocortin receptor agonists (e.g., bremelanotide/PT-141) and vasoactive signaling peptides studied in preclinical research models. The Nexus catalog includes 3 compounds in this category — examples: PT-141, Adamax, VIP. Supplied for in-vitro research use only.

Sexual health research products include PT-141, VIP, and adjacent signaling compounds that do not fit broader peptide families. Nexus keeps this category narrow to reduce search friction and avoid mixing vasoactive or melanocortin-adjacent materials into unrelated groups.

Copy in this category is deliberately conservative. Nexus describes product identity, pathway-adjacent context, and lab verification without consumer claims or personal-use instructions.

Researchers in this category may compare receptor pathway, peptide identity, and signaling family. PT-141, VIP, and Adamax have different research contexts, so the category functions as a discovery surface rather than a claim that the products are mechanistically equivalent.

Product-level pages remain the authoritative source for variant data, COA links, and chemistry details. Internal links help related products remain discoverable without overgeneralizing the category.

Nexus avoids medical and sexual-performance claims. Product pages focus on research-only language, lab-tested context, and batch transparency where records exist.

Compounds in this category are studied in preclinical research models examining melanocortin signaling, vasoactive signaling, and related receptor pharmacology. Common research applications include PT-141 (bremelanotide) research on melanocortin-4 receptor agonism, vasoactive intestinal peptide (VIP) research on VIP-receptor pharmacology and vasoactive signaling, and adamax research as a melanocortin-adjacent research peptide.

The three compounds span two mechanism sub-families: melanocortin-pathway agonists (PT-141 and adamax) and vasoactive intestinal peptide-family research (VIP). PT-141 is the most-studied of the three; VIP differs structurally and mechanistically (28-residue vasoactive peptide rather than a melanocortin-family short peptide).

Common research-stack pairings: PT-141 + MT-2 (across categories) for melanocortin-pathway selectivity research; PT-141 + KPV for alpha-MSH-derived peptide comparison research. VIP is typically studied standalone in vasoactive signaling research.

PT-141 is a small cyclized peptide (~1 kDa) confirmed by HPLC + ESI-MS. VIP is a larger 28-residue peptide (~3.3 kDa) and is characterized by deconvoluted electrospray mass spectrometry. All compounds receive standard HPLC + endotoxin testing.